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1. Introduction 
The total number of rare Mendelian diseases is estimated to be 6,000-7,000 and while each is 
individually rare, together these genetic conditions contribute significantly to morbidity, 
mortality, and healthcare costs. Up to 50% of patients affected by a rare genetic disease never 
receive a diagnosis (Shashi et al., 2014). Usually these patients go through a diagnostic odyssey 
that includes multiple specialist consultations, imaging studies, invasive investigations and 
other time and cost consuming laboratory and genetic tests. In a European study, 25% of 
individuals waited 5-30 years for a diagnosis and in 40% of instances the initial diagnosis was 
wrong, with consequent inappropriate care and unnecessary surgical procedures (EURORDIS, 
EurordisCare2, 2007). Providing a molecularly defined and confirmed diagnosis, in a timely 
manner, is the goal of the scientific community to make an adequate disease management, to 
find knowledge-based targeted treatments, to arrange a surveillance program for later-onset 
comorbidities in some patients, to provide a genetic counseling with respect to recurrence risks 
and prenatal diagnosis options for families. 
It is here that genomics is set to play an increasingly significant role: in the last decade, there 
has been a paradigm shift in the investigation of Mendelian disorders, due to the development 
of powerful new DNA sequencing technologies. This is commonly referred to as Next-
Generation Sequencing (NGS) and is based on the principle of massively parallel sequencing 
(MPS). By facilitating a wider and more detailed examination of the genome, NGS technologies 
may be used to accelerate diagnosis, tailor treatment and ultimately to end the diagnostic 
odyssey altogether. The human genome contains 3 billion base pairs of DNA, but only 1–2% of 
these are coding (i.e. translated into protein). About 85% of all disease-causing mutations in 
monogenic disorders are located in these protein-coding parts of the human genome, that in 
the whole it is called exome. (Rabbani et al., 2014). The development of methods for exome 
sequence capture, called Whole Exome Sequencing (WES) made it possible to investigate all the 
coding variations present in an individual human genome, allowing both the screening of 
known disease-genes and of genes with yet unknown involvement in a particular clinical 
condition, rapidly and cost-effectively. The ﬁrst monogenic disorder to be resolved by WES was 
Miller syndrome, a multiple malformation disorder in 2009. Since then, WES became the 
method of choice for Mendelian disease gene identification (Ng et al., 2010).  
1.1  Whole Exome Sequencing overview 
WES is a NGS method that analyze all the genes present in the genome. WES has the critical 
advantage of permitting the finding of both known and novel disease-causing genes at the 
same time and considering that the great bulk of Mendelian disorders are caused by exonic 
mutations, currently it is the best approach for Mendelian gene identification. Others clear 
benefits are: 
1. cost-effectiveness and rapid strategy for analyzing nearly all the coding regions of the 
genome; 
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2. unbiased sequencing approach, as it does not limit the analysis to a predefined region of few 
basis, making possible to identify genes acting in unexpected pathways or cellular processes; 
3. sample size required for a sufficiently powered study dramatically reduced; 
4. provides new insights into human gene pathways; 
5. crucial for drawing accurate genotype/phenotype correlations; 
6. facilitates clinical diagnostic, both in cases with atypical manifestations, or that require 
extensive or costly evaluation (high genetic heterogeneity), opening the way to specific choice 
of treatment. 
For the first time, this technology has been proved to be successful in the identification of rare 
and extremely rare variants causative of the clinical phenotype under study (Minor Allele 
Frequency; MAF <1% and < 0.5% respectively) also with small numbers of informative cases 
(one trio or few unrelated individuals with the same phenotype), which have been refractory to 
classical approaches. It is possible to study different patterns of inheritance (recessive, 
dominant/de novo, X-linked) with the appropriated strategy of variant filtering. We can assume 
to look for bi-allelic variants for a recessive model (homozygous or compound heterozygous 
and the parents to be obligate carriers for the variant); heterozygous variant for a dominant 
model (only one parent obligate carrier for the variant or none in case of a de novo event); 
homozygous or hemizygous variant for an X-linked model. Genes for recessive diseases are, in 
general, easier to find than genes for dominant disorders because fewer genes in each exome 
are homozygous or compound heterozygous for rare non-synonymous variants. 
WES was designed to find variants in coding regions and UTR’s such as single nucleotide 
polymorphisms (SNPs), small insertions and deletions (indels). Therefore, most of non-coding 
variants escape the technology itself, along with others such as trinucleotide repeats and 
chromosomal rearrangements. Large deletions and duplications (Copy Number Variants or 
CNVs) are also difficult to be detected from exome data although several tools have been 
developed. The four well known WES-based CNVs detection tools are HXMM, CoNIFER, 
ExomeDepth, and CONTRA. Each software uses an algorithm that has its own strengths and 
weaknesses, different minimum and maximum CNV length detection, accuracy. Usually the 
majority of the software are based on the analysis of the read depth detecting the number of 
fragments that mapped in defined genomic regions, and on the comparison between patient 
and controls data. However these measures could be affected by errors caused by inaccurate 
capture of the region for capture kit problem or alignment problems (de Ligt et al., 2013) so 
that they should be always confirmed by another technique.  
The advantages of exome sequencing are clear (Bamshad et al., 2011): 
• nearly all the coding regions can be assayed in a single experiment; 
• it is not necessary to limit the exploration to a pre-defined region and it is possible to identify 
genes acting in unexpected pathways or cellular processes; 
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• the sample size required for a sufficiently powered study is dramatically reduced. 
Apart these advantages, it also has shortcomings, such as: 
• current capture probes can only target exons that have been identified so far; 
• the efficiency of capture probes varies considerably and some sequences fail to be targeted 
by capture probe design; 
• not all templates are sequenced with equal efficiency; 
• not all sequences can be aligned to the reference genome so as to allow base calling; 
• a huge amount of data is produced that requires special competence to be managed. 
The larger challenge however is data interpretation. On average, exome sequencing identifies 
about 20,000 – 25,000 variants, a number that can change in consideration of various factors 
such as different methods used, and ethnicity of samples (Altshuler et al., 2010).  
More than 95% of these variants are known polymorphisms in human populations. 
Strategies for finding causal alleles against this background differ, depending on several factors, 
such as: 
• mode of inheritance of the trait; 
• pedigree or population structure; 
• de novo or inherited variant; 
• extent of locus heterogeneity. 
Another challenge is also to get a comprehensive clinical phenotype that can help to address 
the search towards a particular gene/pathway. Sometimes WES reveals mutations that help the 
clinicians to make the proper diagnosis, and this type of approach from genotype to phenotype 
is called “reverse dysmorphology” (Shaffer et al., 2007; Slavotinek et al., 2009, Glissen et al., 
2011). 
1.2  Rare Mendelian diseases under study. 
Mendelian diseases are defined as occurring in families with a pattern that reflects the 
inheritance of a single causative gene, and follows the Mendel laws, such as transmitted in an 
autosomal dominant, recessive or X-linked manner. However, this simple Mendelian heritability 
can be complicated by incomplete penetrance, variable expressivity, parental effects etc. 
We focused our attention on such rare Mendelian diseases, and we studied a cohort of 
heterogeneous samples affected by the following diseases: Crisponi syndrome/Cold-induced 
sweating syndrome type 1 (CS/CSS1), syndromic Intellectual Disabilities (SID), Progeria-like 
syndrome (PLS), Epileptic Encephalopathy (EE), Osteopetrosis (ARO), Genetic Hearing Loss 
(GHL).  
1.2.1  Crisponi Syndrome/Cold-induced sweating syndrome type 1 (CS/CISS1) 
Crisponi syndrome/Cold-induced sweating syndrome type 1 (CS/CISS1; MIM#272430) is a very 
complex and rare autosomal recessive disorders with a high neonatal mortality rate, due to 
mutations in the CRLF1 gene, encoding for the cytokine receptor-like factor-1 (CRLF1). Before 
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2007 it was thought that CS and CISS1 were two distinct disorders, with CS and CISS1 reported 
for their neonatal and post-neonatal phenotype respectively. In 2007, the identification of 
mutations in the CRLF1 gene led to the conclusion that they were allelic forms of the same 
disease. Afterwards, functional studies on mutated forms of CRLF1, gave the hint that the two 
syndromes, CS and CISS1, actually represent manifestations of one single disorder, with 
different degrees of severity (Crisponi et al., 2007; Dagoneau et al., 2007, Herholz et al., 2011). 
Since the identification of the involvement of the CRLF1 gene in the pathogenesis of the 
syndrome, a molecular genetic testing for CRLF1 mutations is available, allowing for a reliable 
genetic counselling in patients with suspected CS/CISS1.  
CS was initially described in 17 patients from 12 different families in central and southern 
Sardinia, Italy (Crisponi, 1996). The syndrome usually manifests at birth, with hyperthermia and 
abnormal paroxysmal contractions of the facial and oropharyngeal muscles, as well as feeding 
and respiratory difficulties often requiring the use of nasogastric feeding. Physical 
dysmorphisms such as a large face, broad nose and camptodactyly have been described in most 
of CS patients. In most cases patients died before the first month of life due to respiratory 
distress or unexplained episodes of hyperthermia. In the rare surviving CS patients, while 
feeding difficulties and hyperthermia often resolve after infancy, the development of scoliosis 
and sometimes psychomotor retardation occur. In pre-adolescent CS patients, evidence of cold-
induced sweating was reported. 
CISS1, instead, was first described in two Israeli sisters (Sohar et al., 1978) and similar clinical 
phenotype was later reported in two Norwegian brothers along with the detection of mutations 
in the CRLF1 gene (Knappskog et al., 2003). It involves paradoxical sweating at cold ambient 
temperatures on the upper part of the body, along with progressive scoliosis, dysmorphic 
features including a high arched palate, nasal voice and joint contractures. 
The CS/CISS1 syndrome has particularly high prevalence in Sardinia compared with other 
countries. Recent studies in Sardinia reported a incidence of 1/20,700 newborn case with a 
percentage of carriers of 1,4 (Piras et al., 2014). 
The CS/CISS1 syndrome is often not correctly diagnosed due to the extremely complex 
phenotype. The CS/CISS1 syndrome is comprised in a new family of "CNTF receptor-related 
disorders" along with Cold-induced sweating syndrome type 2 (CISS2; MIM#610313), and 
Stüve--Wiedemann syndrome (SWS; MIM#601559), all showing overlapping clinical features. 
CISS2 results from mutations in the CLCF1 gene, while SWS is caused by mutations in the LIFR 
gene (Crisponi et al., 2007). Ciliary neurotrophic factor (CNTF)-receptor pathway is important 
for embryonic development and maintenance of the nervous system and supports the 
differentiation and survival of a wide range of neural cell types during development and in 
adulthood. 
The association of the soluble cytokine receptor CRLF1 with CLCF1 forms a stable heterodimeric 
complex that act as a ligand for CNTF-receptor complex that is composed by gp130 and LIFR 
proteins. The dimerization of gp130/LIFR induces downstream signaling events such as the 
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activation of the Janus kinase 1/STAT3 pathway. Nowadays however, the disease mechanism is 
still poorly understood as well as the physiological role of CRLF1. 
Despite the identification of mutations in the CRLF1 gene provides a definite diagnosis in 
patients with suspected diagnosis of CS/CISS1 syndrome, a fraction of suspected cases remain 
yet genetically unexplained after sequencing of the gene.  
1.2.2 Syndromic Intellectual Disability (SID) 
Intellectual disability (ID), until recently referred to as mental retardation (MR), is not a single 
disease entity but a broad and variable cluster of phenotypes and severity that have impaired 
intellectual abilities as a shared trait. Clinically it is characterized by three criteria (Van 
Bokhoven, 2011): 
1. an intelligence quotient below 70, 
2. limitations in two or more adaptive behaviors, such as communication, self-care, social 
skills etc., 
3. age at onset of mental manifestations before 18 years old. 
ID can be associated with other clinical findings such as dysmorphic features or metabolic 
defects as part of a syndrome or can occur as an isolated phenotype. Taken together, 
syndromic and non-syndromic forms of ID affect approximately 1-3% of the population, with 
the cost of care over a lifetime that can be extremely high. Furthermore, behind the high 
impact of costs, there is the high impact of social and emotional effects on patients and their 
families. 
Although non genetic factors (e.g. infection, trauma, exposition to neurotoxic compound) can 
affect the development and functioning of the nervous system, prenatally, perinatally or 
postnatally, resulting in cognitive impairment, most severe forms of ID have a genetic origin, 
which can account for up to 65% of moderate to severe ID, although this percentage varies 
widely in various studies (Van Bokhoven, 2011). On the basis of our current knowledge, genetic 
causes of ID comprises:  
1. chromosomal rearrangements that result mainly into deleterious gene dosage effect 
(about 30% of cases, Topper et al., 2011),  
2. deregulation of imprinted genes or genomic regions (rare cases, such as Prader Willi 
syndrome and Angelman’s syndrome), 
3. dysfunction of single genes (monogenic causes of ID), which are individually required for 
development of cognitive functions. (about 10% of these are X-linked, Topper et al., 2011; 
Chelly et al., 2006). 
To date, mutations in approximately 450 genes have been implicated in IDs, either non-
syndromic (about 50 genes) or syndromic (about 400 genes) (Van Bokhoven, 2011). Although 
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the number of ID genes is increasing rapidly, currently the genetic etiology of 60% of ID remains 
unexplained (Topper et al., 2011), and the majority of patients remains without a molecular 
diagnosis. 
The main reason why the genetic causes of ID have been difficult to unravel is the high genetic 
and phenotypic heterogeneity. The main causes are monogenic, due to mutations in genes, 
which are individually required for development of cognitive function. Initially, mutations were 
identified in syndromic forms of ID, affecting multiple patients with a consistent and similar 
phenotype (i.e. Fragile X, Rubinstein-Taby syndrome, alpha thalassemia/mental retardation 
syndrome). Then came the discovery of many X-linked genes for both syndromic and non-
syndromic ID, due to their easiness for molecular genetic studies. ID is 30% to 50% more 
common in males than in females, which suggests a relatively high contribution of X-linked ID 
genes (XLID). Physical mapping of X-chromosomal deletions and breakpoints is easier for 
hemizygous chromosomal aberrations than for heterozygous ones. Furthermore, since female 
carriers of an X-chromosomal mutation are usually able to reproduce, large pedigrees with 
multiple affected males are common and available for linkage studies. For many years, research 
into the genetic causes of ID had focused on XLID. However, it has become clear that XLID 
forms account for only about 10% of cases. This means that the vast majority of the underlying 
genetic defects must be autosomal. So far the elucidation of autosomal ID genes both 
syndromic and non-syndromic has been delaying, mainly due to the lack of suitable families for 
accurate mapping of the genetic defect. For severe forms of ID, autosomal dominant 
inheritance is rare because most affected individuals do not reproduce, and recent evidence 
revealed a high percentage of de novo mutations (Vissers et al., 2010). The molecular 
explanation of autosomal recessive ID is still at the beginning, because small family sizes and 
infrequent parental consanguinity especially in Western societies. Non-syndromic forms (NS-
ARID) are problematic because they are clinically indistinguishable. During the past few years, 
significant progress has been made, facilitated by the use of high density SNP microarrays and 
subsequent application of homozigosity mapping in large consanguineous families. A further 
boost has been done by the introduction of exome enrichment and next generation 
sequencing, which has the potential to identify all kinds of genetic variation at base-pair 
resolution throughout the human genome in a single experiment, as a cost-effective and fast 
strategy. 
The increase in the number of ID genes being identified, show extended and complex functional 
interaction networks converging into common molecular and cellular pathways, including 
neurogenesis, neuronal migration, synaptic functions, transcription and translation. A growing 
output is highlighting the extent of epigenetic involvement in neurological disease. So far 
approximately 10 ID genes encode proteins that have a direct role in chromatin modification 
(epigenetic writers). Another group of approximately 20 genes encodes proteins, which 
indirectly modulate the chromatin structure (epigenetic readers and maintenance) (Van 
Bokhoven, 2011). 
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It can be expected in general that disruption of the components of the same molecular network 
will have a similar phenotypic effect. Then, even without knowing which gene is involved in an 
individual ID, it might be possible to develop tests for specific biochemical assays that can 
assess whether the activity of certain pathways is deficient. There is growing evidence that 
mutations in many of the known ID genes give rise to a high degree of clinical variability, that 
can be a reflection of the type of mutation or of other genetic and environmental factors, and 
to the association with a variety of different Cognitive Disorders (CDs). There is a high co-
morbidity commonly observed between ID and other CDs, such as autism (ASD), attention 
deficit hyperactivity disorder (ADHD), depression and other behavioral problems. This 
phenotypic overlap between ID and various CDs is mirrored at the genetic level, all supporting 
the notion that they share a common molecular etiology.  
This information can facilitate the definition of new syndromes associated with ID, stating more 
accurate genotype/phenotype correlations and using an approach from genotype to phenotype 
(“reverse dysmorphology”, Shaffer et al., 2007; Slavotinek et al., 2008). 
This classification would provide bases and frameworks for understanding physiopathological 
mechanisms underlying ID, and this is a fundamental prerequisite for drug development.  
1.2.3 Progeria like syndrome (PLS) 
Progeroid syndromes (PSs) constitute a group of rare monogenic disorders characterized by 
clinical features mimicking physiological aging at an early age. In some of these syndromes, 
biological hallmarks of aging are also present, whereas in others, a link with physiological aging, 
if any, remains to be elucidated. These syndromes are clinically and genetically heterogeneous 
and most of them, including Werner syndrome and Hutchinson–Gilford progeria, are known as 
‘segmental aging syndromes’, as they do not feature all aspects usually associated to 
physiological aging. Several causative genes have been identified. These can be separated in 
subcategories corresponding to: (i) genes encoding DNA repair factors, in particular, DNA 
helicases, which maintain the integrity of a cell decreasing the predisposition to cancer and 
aging phenotypes; (ii) genes affecting the structure or post-translational maturation of lamin A 
(LMNA), a major nuclear component that determines the shape and integrity of the nucleus. 
Patients can have a complicated phenotype with the association of others disease like 
lipodystrophy or diabetes.  
1.2.4 Epileptic Encephalophaty (EE) 
Epilepsies are a group of neurodevelopmental disorders characterized by spontaneous 
recurrent seizures; about 20-30% of epilepsies are caused by acquired conditions: like tumors, 
drugs and alcohol abuse, ictus, brain infections, and head trauma, while the remaining 70-80% 
are due to genetic factors (Jabbari & Nürnberg, 2016). Epilepsies can be divided into about 3 
major groups: Genetic Generalized Epilepsy (GGE), Focal Epilepsy, and Epileptic Encephalopathy 
(EE). Medical tests for the detection of the disease are EEG or brain Imaging (MRI), but are 
inconclusive for some types of epilepsy.  
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All the classes of the disease are genetically heterogeneous and several genes implicated in its 
pathogenesis were discovered, and comprise genes involved in the formation of ion channel 
and neurotransmitters receptors, intracellular signaling, synaptic vesicles, chromatin 
remodeling, transcriptional regulation and rapamycin signaling (mTOR). This led to the 
identification of different pharmacological targets for the various types of epilepsies. Therefore, 
it is critical to know the genetic cause in the patient in order to find the optimal treatment. 
1.2.5 Osteopetrosis (ARO) 
Osteopetrosis are a group of heterogeneous rare genetically bones disorders, characterized by 
increased bone density detectable with radiographic tests. It is caused by failure of osteoclast 
development or function, and mutations in at least ten genes have been identified as causative 
in humans, accounting for 70% of all cases. This lead to an increased likelihood of fractures.  
Osteopetrotic conditions vary greatly in their presentation and severity, ranging from neonatal 
onset with life-threatening complications such as bone marrow failure to the incidental finding 
of osteopetrosis on radiographs. The overall prevalence and incidence of these conditions is 
difficult to estimate but autosomal recessive malignant osteopetrosis (ARO) has an incidence of 
1/ 250,000 births, and autosomal dominant osteopetrosis (ADO) has an incidence of 1 in 20,000 
births (Orphanet) (Bénichou et al., 2001). 
Classic ARO is characterized by fractures, short stature, compressive neuropathies, 
hypocalcaemia with attendant tetanic seizures, and life-threatening pancytopenia. The 
presence of primary neurodegeneration, intellectual deficit, skin and immune system 
involvement, or renal tubular acidosis may point to rarer osteopetrosis variants, whereas onset 
of primarily skeletal manifestations such as fractures and osteomyelitis in late childhood or 
adolescence is typical of ADO. 
1.2.6 Genetic hearing loss (GHL) 
Hearing loss is a common disorder developed with age, congenital malformation, infection in 
utero or during life, and some forms are genetically hereditable. Genetic hearing loss 
prevalence is 1/10,000 in the general population. This rare Mendelian disease could be 
syndromic or non-syndromic, with autosomal recessive or autosomal dominant transmission, 
and very few cases reported variant in X-linked or in mitochondrial genes. Syndromic forms are 
about 30% and the non-syndromic are about 70%. Genetic hearing loss are a heterogeneous 
group of disease with many genes identified so far. Degree of severity is variable and often 
affects children. The most involved gene in Spain and Italy for severe non-syndromic genetic 
hearing loss is GJB2, with about 80-90% respectively of cases. Studies in consanguineous 
populations have been useful to discover many genes underlying this pathology. Patients 
should be evaluated by a team of experts, including an otolaryngologist, a clinical geneticist, a 
pediatrician, a teacher of the deaf, a neurologist, a pediatric ophthalmologist. Some severe 
cases could be resolved by cochlea implantation and others by hearing aids or vibrotactile 
devices. (Smith et al, 1999- 2014) 
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1.3 Rationale 
We speculated that others genes could be involved in our cases affected by the above listed 
diseases and that the WES approach would be the best to find such genes. Since the publication 
of the first successful application of WES for gene discovering in rare Mendelian disorders of 
unknown cause (Ng et al., 2010), it has been shown that exome sequencing of a small number 
of unrelated affected individuals (4-10) with a similar phenotype is a powerful approach to 
detect high penetrance disease mutations, especially for recessive disorders. The number of 
genes homozygous or compound heterozygous for rare nonsynonymous variants in multiple 
affected patients will decrease rapidly resulting in less candidate genes for follow-up (overlap 
strategy) (Ng et al., 2009; Gilissen et al., 2012). 
We believe that this approach will have a great chance to succeed in delineating the genetic 
causes of the rare diseases under study. In particular, this will help in: 
1. making a molecular diagnosis in a larger number of subjects; 
2. implementing an existing map and networks of rare disease causative genes; 
3. defining new syndromes through the so-called “reverse dysmorphology”, i.e., using an 
approach from genotype to phenotype; 
4. providing excellent opportunities for knowledge-based therapeutic interventions. 
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2. Material and Methods 
We have selected 25 families with different rare diseases to be enrolled in this project, whose 
goal was to discovered new genes involved in their pathogenesis by using the approach of the 
WES. The selected families were affected by: 
 Crisponi syndrome/Cold-induced sweating syndrome type 1 (CS/CISS1); 10 families of 
various ethnicities. These families were recruited in collaboration with Dr. Laura 
Crisponi from CNR-IRGB, Cagliari and Prof. Frank Rutsch from the Department of 
General Pediatrics, Muenster University Children’s Hospital, Muenster, Germany. 
 Syndromic Intellectual Disabilities (SID); 9 Sardinian families. These families were 
recruited in collaboration with Prof. Sotgiu and Dr. Serra from the Institute of Child 
Neuropsychiatry, University of Sassari. 
 Progeroid-like syndrome (PLS); 1 Sardinian family, recruited in collaboration with Dr. 
Cottoni from Department of Surgical Sciences, microsurgical and Medical – 
Dermatology, University of Sassari.  
 Osteopetrosis autosomic recessive (ARO); 2 Italian families recruited in collaboration 
with Dr. Sobacchi from the CNR-IRGB division of Milan, Humanitas Clinical and Research 
Institute. 
 Genetic Hearing Loss (GHL); 1 Omani family recruited in collaboration with Prof. Romeo 
from University of Bologna and Dr. Pippucci from Laboratory of Medical Genetic, 
Policlinico S. Orsola-Malpighi (BO). 
 Epileptic Encephalophaty (EE); 1 Brasilian and 1 Sardinian family, recruited in 
collaboration with Dr. Rita Maria Alves from the Catholic University of Salvador (Brasil) 
and with Dr. Dario Pruna from the Unit of Epilepsy, Department Psychiatry and 
Neurology Pediatric, Hospital Brotzu Cagliari. 
2.1 Patients’ selection, samples acquisition and DNA extraction 
All the individuals enrolled in the study (probands and parents where available) signed an 
informed consent approved by the Ethics Committee of the referent clinical centers drawn up 
according to current legislation.  
Blood samples or already extracted DNA from these individuals were sent to the IRGB-CNR 
Institute in Cagliari and anonymized with a code composed by a suffix and a progressive 
number (example: rare_01 or CS_01 or AV_01) that has been used throughout the entire 
project and processed for DNA extraction using a standard salting out protocol.  
In brief: red blood cells lysis and separation of a white pellet of white blood cells were obtained 
by osmotic lysis. The cell pellet was resuspended in a lysis buffer, SDS 10% and protein kinase K. 
At the end of an incubation, NaCl 6M was added and vortexed to precipitate the proteins. The 
supernatant was transferred into a new tube containing isopropanol and DNA was harvested 
with a pipette tip and dipped in a 70% ethanol Eppendorf tube. Finally, the tubes were 
centrifuged to pellet down the DNA. Ethanol was discarded and DNA air-dried. All the samples 
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were resuspended in TE 1-0,1 mM. DNA concentration and purity were assessed using the 
Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific, MA, USA). Furthermore, 
samples underwent an electrophoresis in 1% agarose gel to evaluated DNA degradation, and 
concentration of double stranded DNA was measured in Qubit 2.0 fluorometer using BR dsDNA 
Assay Kit (Invitrogen by Life Technologies). 
2.2 Whole-Exome Sequencing workflow and NGS Sequencing 
Initially we exome sequenced the samples using the TruSeq Exome Library Prep Kit (Illumina) 
and later with the Nextera Expanded Exome Enrichment Kit (Illumina) when this replaced the 
previous one. Both contains 62 Mb of genomic content, including exons, UTRs and miRNA (> 
340,000 95mer probes to enrich about 200,000 exons spanning 20,794 genes). The Nextera kit 
allowed the preparation of the genomic DNA library and the exome capture by hybridization in 
just 3 days instead of 1 week, with an input quantity of DNA of 50 ng instead of 1 µg. 
In general with all the kits in commerce, the exome library preparation consists of: 
fragmentation, repair of the blunt ended, adenylation, ligation of the adapters, a first step of 
PCR, hybridization and capture with biotinylate exome probes created in target regions, 
precipitation with the use of streptavidin beads, and a second step of PCR; all interspersed by 
various purification steps. Adapters contain unique index sequences ligated to sample 
fragments so allowing the pool of more samples and the unique identification of the sequence 
reads during downstream analysis. Furthermore, with the Nextera kit the fragmentation step is 
enzymatic rather than mechanic, so being more time saving. The last step is the validation of 
the enriched library performed by the Agilent 2100 BioAnalyzer with DNA 1000 Kit and/or High 
Sensitivity DNA Kit, and Qubit 2.0 using BR dsDNA Assay Kit. Libraries were loaded on the cBot 
System (Illumina) to create clonal clusters on the flow cell and then sequenced on the HiSeq 
2000 Instrument and analyzed with the Illumina extraction pipeline, that consist in a base-
calling and imaging analysis performed locally by RTA software. The HiSeq 2000 uses the 
Sequencing By Synthesis (SBS) method: a massively parallel sequencing of short reads using 
solid phase sequencing by reversible terminators, able to generate about 600-700 Gb of 
sequence from over 1 billion clusters in the form of 2×100 base reads (paired-end sequencing) 
from 2 flow cells in about 11 days with very low error rates (< 1%). We obtained a medium 
coverage of about 80X for each sample and we were able to run 24 samples in a single flow cell. 
The NGS Facility in Pula is available to IRGB and is directly connected, with a high-performance 
computing center and a fully automated infrastructure to support the bioinformatics analysis of 
sequencing data. Furthermore, an optimized variant calling pipeline for WES was developed in 
collaboration with Center for Advanced Studies, Research and Development in Sardinia (CRS4) 
during the last 3 years for the identification of SNPs, indels and CNVs. These analyses have been 
conducted in collaboration with Dr. Fotia’s team at the CRS4 Biosciences research and 
development sector. 
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2.3 Sequence analysis and variant calling pipeline 
Demultiplexing analysis and generation of FastQ files for the variant calling analysis were 
implemented in Orione, a Galaxy-based framework consisting of publicly available research 
software and specifically designed pipelines to build complex, reproducible workflows for next-
generation sequencing data analysis (Cuccuru et al., 2014). It is part of an ongoing project at 
CRS4 to integrate Galaxy with Hadoop-based tools to provide scalable computing and a 
specialized version of OMERO to model biomedical data and the chain of actions that connect 
them. Galaxy is used to manage all workflow based operations, while a custom “automator” 
daemon is used to execute and monitor workflow progress form the HiSeq instrument to the 
FastQ files and to link workflows to each other. One of the main advantages of this approach is 
that Galaxy tracks all operations with its histories. This infrastructure is already used in 
production at the CRS4 for the automated processing of sequencing data. 
In details, the paired-end sequence reads were aligned to the human genome (hg19) with the 
BWA-MEM aligner (BWA v.0.7.5) (Li, 2013). SAMtools were used for converting (SAM/BAM), 
sorting and indexing alignments. Quality metrics and coverage statistics were calculated with 
FASTQC and Picard tools. Initial mappings were processed using the GATK framework (GATK 
v.2.8.1) (McKenna et al., 2010) according to their Best Practices recommendations. Briefly, 
reads were locally realigned around known insertion and deletion (INDELs) sites, in fact those 
zones are hardly to mapping correctly so is necessary this step to correct errors made from the 
first alignment. Then, PCR and optical duplicates were marked with Picard tools (v.1.119) and 
excluded from downstream analysis. Finally, raw base quality scores were recalibrated to adjust 
for quality variation due to machine cycle and sequence context, and Single Nucleotide 
Polymorphisms (SNPs) and insertions/deletions (INDELs) were identified using GATK Unified 
Genotyper. Highly accurate variant calls are identified with GATK hard filters. Variants were 
classified as known or novel variants based on dbSNP146. Different tools (GATK Variant 
Annotator, SnpSift and SnpEff (Cingolani et al., 2012), KGGSeq (Li et al., 2012), SilVA (Buske et 
al., 2013)) were used to annotate variants with position in UCSC, RefGene, Ensembl and 
GENCODE transcripts, OMIM, ClinVar and DDD annotations, potential false positive signals as 
described in Fuentes Fajardo et al., 2012, maternally or paternally imprinted genes (Joshi et al., 
2016), presence of pseudogenes, allele frequency in dbSNP141, 1000 Genome Project, 
ESP6500, ExAC, Evade v.5 (an internal exome database of ~500 samples) and in a Sardinian 
population database derived from whole genome sequencing (WGS) of 3,500 samples (Sidore 
et al., 2015); sequence conservation, predicted pathogenicity according to different models 
(non-synonymous variants: CADD, SIFT, Polyphen2, LRT, MutationTaster, MutationAssessor and 
FATHMM retrieved from dbNSFP v. 2.9 (Liu et al., 2013); synonymous variants: SilVA), evidences 
from literature automatically retrieved from PubMed by co-citation of keywords of interest and 
the genes in which the variants are located.  
In consanguineous families homozygous regions were studied by H3M2 (Magi et al., 2014) and 
PLINK software. Sequence data were analyzed with CoNIFER software (Copy Number Inference 
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From Exome Reads; Krumm et al., 2012) for the discovery of CNVs in all sequenced patients. 
CNV calls were annotated with CLINGEN and DGV databases. 
2.4 Biological interpretation and identification of causal alleles 
NGS identifies between 20,000 and 50,000 high quality variants per exome, depending on the 
kit used. Prioritizing variants in WES studies of Mendelian diseases to finally identify the causal 
allele can be done at different levels and it is very challenging. 
1. - Variant-gene level:  
1.1 - Frequency: in rare severe Mendelian disorders, causal variants generally show complete 
penetrance and are rare, and therefore not present in public databases. Ideally, individuals in 
the reference population should have the same origin as the sample under investigation. 
However, because local population frequencies are not always available, public databases are 
used. Common variants deposited in public databases (1000 Genomes Project, ESP6500, ExAC, 
and dbSNP) are filtered out according to an adjustable allele frequency threshold. As most of 
the diseases under study are relatively uncommon and ideally caused by rare pathogenic 
variants, a filtering exclusion based on a minor allele frequency (MAF)>1% is well powered 
(Bamshad et al., 2011). However, caution is necessary given that some of the databases also 
include patients. Furthermore, an in-house database of about 500 exomes (Evade v.5) available 
at CRS4 provides a useful filter to remove additional variants, with a 75% increase of the 
filtering power, for frequency or platform/laboratory artifacts.  
1.2 - Gene features: as severe Mendelian disorders are more likely to be caused by non-
synonymous mutations (missense, nonsense, splice-site defects, frameshift and non-frameshift 
indels), focusing only on this functional class of variants narrows down the number of 
candidates. Because not all non-synonymous variants contribute equally to affect function of 
coded proteins, a predicted effect on protein function and on whether it is potentially disease-
casual is challenging especially for missense variants. 
2. - Genetic level:  
2.1 - Pedigree information: affected family members usually share the genomic segment 
harboring the causal mutation(s). In families with two or more affected siblings, we planned to 
take advantage of an approach, based upon the identification of chromosomal regions identical 
by descent (IBD) based on genotype data derived from exome sequencing. Therefore, variants 
inside the IBD regions found among the affected family members are of primary interest.  
2.2 - Mode of inheritance of disease can also be used to effectively exclude impossible disease-
causal variants. We can assume that there are bi-allelic variants for a recessive model 
(homozygous or compound heterozygous with the parents obligate carriers for the variant); 
heterozygous variant for a dominant model (only one parent obligate carrier for the variant or 
none in case of a de novo event); or hemizygous variant for an X-linked model.  
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3. Knowledge level: disease-network analysis added a complementary layer of information to 
the sequencing data. It predicted role in a biological pathway and/or interaction with genes or 
proteins that were known to cause a similar phenotype and could be used at different steps of 
analysis. A primary detailed network analysis of the gene(s) harboring variants genetically and 
biologically validated facilitated the clarification of their putative role in the pathogenesis of the 
syndrome. It could be expected that disruption of the same molecular network could have a 
similar phenotypic effect in general. 
2.5 Genetic validation of sequence variants 
Each sequence variant identified during the screening phase as potential candidate in the 
pathogenesis of the diseases under study, has been genetically validated by traditional Sanger 
sequencing and disease-segregation analyses in the family. All family members were sequenced 
by using the sequencer ABI Applied Biosystem 3730 DNA Analyzer, and all the primers were 
designed manually or with the program Primer3. 
PCR was performed in 25µl of the total volume, and were used: 10 to 50 ng of DNA for 
problematic samples (particularly degraded samples), 1X buffer, MgCl2 2 mM, 0,12 µM of 
primers, 0,4 U of Taq Polymerase and 0,2 mM of each dNTPs. 
To amplify problematic GC rich sequences, 5 µl of Betaine 5M were added to the mix. 
PCR purification was done using Exosap according to manufacturer’s protocol, Big Dye v1.1 and 
relative Buffer 5X were used for sequencing the PCR fragment. Then the sequence reaction was 
precipitated with 95% ethanol, sodium acetate 3M Ph 5.4.  
2.6 Biological validation of sequence variants 
In parallel with genetic validation, the most promising variants will be studied to evaluate their 
functional effect and role.  
  
 Dott.ssa Manuela Oppo 
Discovering rare-disease-causing genes in the Whole Exome Sequencing (WES) era: analysis of a heterogeneous cohort of families with rare Mendelian diseases. 
Tesi di Dottorato in Scienze Biomediche   Curriculum: Genetica Medica 
 Università degli Studi di Sassari  Pag. 17 
 
3. Results 
3.1 CS/CISS1 families results 
In collaboration with Dr. Laura Crisponi from CNR-IRGB, Cagliari and Prof. Frank Rutsch from the 
Department of General Pediatrics, Muenster University Children’s Hospital, Muenster, 
Germany, we had available a cohort of 35 patients with clinical suspect of CS/CISS1 syndrome 
but negative to mutations in the CRLF1 gene. To assess the similarity of their clinical phenotype 
with the CS/CISS1 phenotype, which is quite complex, we decided to focus on the infantile 
phenotype. We selected the four main typical CS symptoms: hyperthermia in the first months 
of life, feeding difficulties, contraction of oropharyngeal muscles and camptodactyly. To 
simplify the research we subdivided patients in 3 ranks: patients with all 4 of the major 
symptoms during first months of life, were assigned to rank 1, patients with 3 or 2 of those 
symptoms to rank 2 and those with only 1 symptoms to rank 3. 
So far, we classified 11 cases (2 sibs) within rank 1 that have been prioritized for WES.  
 
 
Figure 1. CS/CISS1 Pedigree of rank 1 families. Samples analyzed by WES are enclosed in red squares. Pedigree 
symbols and colors are defined as follows: square, male; circle, female; white, unaffected; black, affected; double 
horizontal lines, consanguineous marriage. 
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3.1.1 Families C, F, G, L 
WES analysis followed by Sanger sequencing in 3 consanguineous Turkish families identified a 
common gene, kelch-like family member 7 (KLHL7 MIM: 611119; GenBank: NM_001031710.2), 
harboring the following private and potential deleterious mutations, all in homozygous state: 
M1 (c.1261T>A:p.Cys421Ser) in family C, M2 (c.1022delT:p.Leu341Trpfs∗9) in family F, and M3 
(c.1258C>T:p.Arg420Cys) in family G (Figures 1 and 2). All the parents were found to be 
heterozygous carriers. The putative pathogenic variants M1 and M2 were absent in all the 
reference genomic database used (see material and methods) while M3 
(c.1258C>T:p.Arg420Cys) in family G was present as rs780705654 in dbSNP146 and in ExAC with 
2 heterozygotes (1 East Asian, 1 European non-Finnish) on 121,411 total alleles (C 0.99998355; 
T 0.00001647). To assay the contribution of KLHL7 to the CS/CISS1-like phenotype, we analyzed 
by Sanger sequencing all the coding sequence and intron-exon junctions of KLHL7 in the 20 
remaining samples of the entire cohort of case subjects negative to mutations in CRLF1 (rank 2, 
and 3). We identified one additional KLHL7 missense variant, M4 (c.1115G>A:p.Arg372Gln) in 
the affected individual from family L (of Turkish origin and consanguineous) belonging to the 
rank 2 group. 
 
 
Figure 2. Pedigree and Sanger sequencing of the KLHL7 mutations identified in the four Turkish consanguineous 
families. Mutation status of KLHL7 is indicated beneath symbols for each subject: +/-, heterozygous carriers; +/+, 
homozygous. Panels shows wildtype, heterozygous, and homozygous status for M1 (c.1261T>A:p.Cys421Ser), M2 
(c.1022delT:p.Leu341Trpfs*9), M3 (c.1258C>T:p.Arg420Cys) and M4 (c.1115G>A:p.Arg372Gln), respectively 
(Angius et al., 2016). 
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Recently mutations in KLHL7 were found to be associated to an autosomic dominant form of 
Retinitis Pigmentosa (adRP42; MIM#612943). The KLHL7 gene codes for the BTB-Kelch protein 
of 586 aa, which is formed by three domains: BTB, Kelch and BACK. It was identified to be a new 
sub-unit of the substrate recognition component of the CUL3-Ubiquitin ligase complex. In 
particular, KLHL7 forms a dimer with CUL3 through the BTB and BACK domains and exerts its E3 
activity polyubiquinating target protein(s) and mediating protein degradation by the 
proteasome (Kigoshi et al., 2011). Ubiquitination failure leads to an accumulation of the 
substrate that, in the long term, leads to cell toxicity. While in RP42 all the mutations are 
located in the BACK domain, the variants found in our CS/CISS1-like patients reside in the Kelch 
domain (Figure 3). 
 
Figure 3. Schematic representation of the KLHL7 protein. Substitutions reported here and in Friedman et al.,2009 
are indicated. The corresponding positions are referred to the KLHL7 splice isoform 1 (Angius et al., 2016). 
 
Besides the p.Leu341Trpfs*9 substitution which results in a premature termination codon and 
an almost complete loss of the Kelch domain from the protein, the other 3 missense mutations 
had an high degree of conservation among species and were all predicted to be pathogenic 
with several prediction tools. In silico analysis showed that Arg420 and Arg372 are situated 
within a connection loop between Kelch motifs, and are not exposed to the protein substrate, 
but they form a salt bridge that contribute to stabilized the structure and maybe permit the 
substrate ligation. Cys421 forms a hydrogen bridge, is partially expose to the solvent and could 
thus influence the substrate binding to some extent. 
Co-localization studies of either KLHL7 WT or missense mutants with CUL3, pointed out that 
such missense variants do not have any influence on CUL3 binding, so we speculated that 
variants in the Kelch domain alter the binding between KLHL7 and the target substrate(s), not 
allowing their ubiquitination and degradation, with consequence accumulation and cellular 
toxicity. 
Unfortunately, the substrate(s) bound to KLHL7 are so far unknown, and our proposed 
hypothesis is one among several. The disruption of the structural bridges in the Kelch domain 
could also affect the catalytic E3 activity or the stability of the protein. Therefore, future studies 
determining the target substrates of KLHL7 will be of great importance in better understanding 
the pathophysiologic role of KLHL7. A critical assessment of the retinal phenotype in our alive 
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CS/CISS1-like probands revealed an early form of RP. These data support the pathogenic role of 
KLHL7 in this phenotype. Find out whether KLHL7 and CRLF1 functionally converge may have 
important implications in the search for novel disease-associated genes and pharmacological 
targets.  
The results of this study have been published in 2016 in the American Journal of Human 
Genetics (Angius et al., 2016). 
3.1.2 Families A and D. 
We identified 2 de novo heterozygous variants in the NALCN gene (c.1800C>A:p.D600E and 
c.1571G>A:p.S524N) in the probands of 2 non consanguineous families, one of Wales and the 
other of Irish/Scottish origin (Figure 1). Prediction software indicate these 2 variants as ‘disease 
causing’. The gene codes for an ion channel voltage independent, non-selective, permeable to 
ions Na+, K+ and Ca2+. It is responsible of the background due to the loss of sodium ions in 
neurons and controls neuronal excitability. Furthermore, it is necessary for normal respiratory 
function and for neonatal survival (Lu et al., 2007). It has been described to be involved, as an 
autosomal recessive trait in the infantile hypotonia with psychomotor retardation and 
characteristic facies (IHPRF, MIM#615419) and recently as autosomal dominant/de novo in the 
CLIFAHDD syndrome (MIM#616266; Chong et al., 2015; Aoyagi et al., 2015; Saitsu et al., 2016; 
Bend et al., 2016; Wang et al., 2016), characterized by congenital contractures of the legs and 
face, hypotonia and developmental delay. For a child died 12 days after birth, it was 
hypothesized a clinical suspect of CS/CISS1 syndrome, due to the overlap of the clinical 
phenotype. Sanger sequencing of the CRLF1 gene did not show any variation. WES instead 
identified a mutation in the NALCN gene.  
The variants reported causing the CLIFAHDD syndrome were found in the S5 and S6 segments 
of domains I-IV that forms the channel pore, while those reported in IHPRF syndrome alter the 
S3 segment of domain IV. This means that a variation in different regions of NALCN protein 
involves different functions of the channel and lead to different Mendelian disorders. Patients 
described in this study also have camptodactyly and many other symptoms related to the 
CS/CISS1 syndrome.  
The two de novo missense variants (c.1800C>A:p.D600E and c.1571G>A:p.S524N) found in our 
probands, lie in the S5 and S6 segments of the domain II, but were not reported before in 
literature associated to CLIFAHDD. However it is curious that the variant c.1800C>A:p.D600E 
has been described by Bend et al., 2016, referring to a variant found in C. Elegans, organism 
used to study variants motor effects, because C. Elegans has 2 NALCN homologous genes 
responsible of Na+ conductance. Bend described this de novo variant as a gain of function, 
which gives identical severe effects as those described in our proband. These findings underline 
as CLIFAHDD and CS/CISS1 syndrome have an important phenotypic overlap, making the clinical 
diagnosis even more complex. Functional studies are necessary to evaluate if the 2 mutated 
proteins are involved in the same functional pathway. 
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3.1.3 Family E 
We found a de novo heterozygous missense variant in the SCN2A gene (c.2567G>A:p.R856Q) in 
the proband of a Swedish non consanguineous family (Figure 1). This variant was predicted as 
deleterious by different prediction tools. This gene was previously reported in literature as 
implicated in a group of autosomal dominant diseases, like early infantile epileptic 
encephalopathy (including Ohtahara syndrome), neonatal-infantile epileptic family benign 
crisis, West syndrome, Dravet syndrome. SCN2A encodes a protein that is part of the α sub-
units voltage-dependent Na+ channel. This channel controls the Na+ ions permeability and the 
consequent membrane excitability, and is responsible for the formation of the membrane 
potential and its propagation in the cells including nerves, muscles and cells of the 
neuroendocrine system. Structurally, the channels are formed by α sub-units that form the 
pore, which can be associated with 1 or more subunits β. The α subunits are composed of 
homologous domains each of which contains six transmembrane segments (S1-6); 5 of these 
are hydrophobic (S1, S2, S3, S5, S6) while the S4 segment is positively charged and acts as the 
channel sensor. Our missense variant (c.2567G>A:p.R856Q) resides in the S4 segment. A 
different variant (c.2559G>A:p:R853Q) (Nakamura et al., 2013) was reported associated to 
West syndrome.  
A critical reassessment of the clinical phenotype in our patient in the light of what we have 
found at the molecular level is in progress. In addition, more patients and data are needed to 
understand its role in the pathology. 
3.1.4 Families B and AB  
WES analysis in 2 families, 1 Spanish and 1 Rumanian identified 2 distinct variants, 1 de novo 
heterozygous frameshift (c.2064-2074delTGGCAGGCACC:p.689fs) and 1 frameshift 
(c.1996insC:p.Q666fs) paternally inherited in the MAGEL2 gene. Recently a new syndrome 
called Schaaf-Yang has been described (MIM#615547; Schaaf et al., 2013), due to heterozygous 
frameshift variants in the MAGEL2 gene, inherited paternally and subject to maternal 
imprinting. MAGEL2 belongs to the group of ubiquitin protein dependent (type 2) who are 
involved in important biological and pathological processes; however biological and cellular 
mechanisms are still unknown. MAGEL2 was found associated with TRIM27. The main signs of 
the Schaaf-Yang syndrome are: neonatal hypotonia, feeding problems, contractures and 
developmental delay, which consistently overlap with those reported for the CS/CISS1 
syndrome in the neonatal period. Most affected children do not survive because of respiratory 
problems and sucking defects. It is interesting to note that our paternally inherited mutation 
has already been described by Fountain et al., in 2017, as associated with the Schaaf-Yang 
syndrome. The discovery of this variant in 18 patients confirmed that it is a mutational hotspot. 
Various studies have been conducted on mouse models to try to identify the pathophysiological 
mechanisms of the syndrome and the correlation between genotype and phenotype. From 
these studies, it emerged that MAGEL2 influences the hypothalamic feeding circuits including 
control and development of the muscle that allows the act of sucking, essential for the 
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newborn's survival (Bischof et al., 2016; Kamaludin et al., 2016). The study by Schaller et al., 
2010 suggests that an injection of oxytocin from 3 to 5 hours after birth allows a higher survival 
rate among Magel2 KO mice. The authors proposed this therapy for other syndromes with 
defects of sucking at birth. 
 
The results of these studies have been in part already published (Angius et al., 2016) and in part 
are under manuscripts preparation. 
 
3.2 Syndromic Intellectual Disability families results  
 
 
Figure 4. SID pedigree families. Samples analyzed by WES are enclosed in red squares. Symbols: black circles 
joined by lines that form a triangular shape: monozygotic twins. 
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3.2.1 Family 2 
This family is composed of both parents and two children with suspected Filippi syndrome 
(MIM#272440), with a milder phenotype in the youngest (Figure 4). The entire family unit was 
sequenced and filtered for an autosomal recessive inheritance pattern to search for causal 
variants either in homozygosity or as heterozygous compound. The analysis pipeline identified a 
homozygous frameshift variant (c.571insA:p.I191fs) in the CKAP2L gene (cytoskeleton 
associated protein-like 2) (Yumoto et al., 2013), encoding a microtubule-associated protein, 
essential for the formation of the mitotic spindle and for the cell cycle in neural progenitor 
cells. Sanger sequencing analysis confirmed the presence of this variant in homozygous state in 
the two affected brothers and in heterozygous state in the parents. 
In order to assess the pathogenic role of the gene in the syndrome under study, we proceeded 
to the analysis of CKAP2L in other 6 patients with similar clinical phenotype, recruited in an 
international collaboration. Unfortunately, in none of these we have highlighted putative 
pathogenic variants. 
The same family enrolled in our study was also studied in another Italian research center, which 
unfortunately published before us a paper reporting the same cases and the same molecular 
conclusions (Hussain et al., 2014). 
3.2.2 Family 3 
This family comprises: both parents, 1 healthy daughter and 2 daughters affected by SID (Figure 
4). Assuming autosomal recessive or autosomal dominant inheritance, we have not identified 
any possible causative variant. Using CoNIFER and ExomeDepth software, we found a large 
deletion (about 90 Kb) in the 2 patients that include the entire NCOR1 gene, recently associated 
with autism (Wang et al., 2016). This CNV need to be validated by a different method and the 
de novo germline mosaicism needs to be investigated.  
3.2.3 Family 4 
This family consists of parents, a son and a daughter with different clinical phenotypes related 
to SID (Figure 4). The youngest daughter shows motility and generalized strength deficits and 
severe hypotonia in particular in the lower limbs. After a first analysis in which we hypothesized 
an autosomal recessive pattern, we focused our attention on a de novo missense variant 
(c.3082A>G:p.I1028V) in the CHD7 gene present in the sister but not in brother. This variant has 
already been described as responsible for the Charge syndrome (MIM#214800; Vissers et al., 
2004). This result is currently under evaluation by the referring clinicians to assess its putative 
role in the clinical phenotype of the patient. 
3.2.4 Family 15 
This family consists of both parents and 2 daughters affected by SID (Figure 4). We failed to 
identify any homozygous or compound variants of interest, assuming that the disease was 
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under an autosomal recessive model of transmission. Assuming an autosomal dominant 
inheritance, we identified, in both patients, a variant (c.342A>C:p.R114S) in the CHD8 gene, 
that was previously associated with autosomal dominant autism (Bernier et al., 2014; Wang et 
al., 2016). The variant is a missense mutation maternally inherited, not present in any public 
databases and predicted as ‘disease causing’. Clinicians are currently assessing its compatibility 
with the clinical phenotype of the two sisters. 
3.2.5 Family 21 
This family is composed of both parents, one male child with mild syndromic ID, and two 
healthy children (Figure 4). All family members were analyzed by WES. In this case we searched 
for putative causal variants fitting different inheritance models. This study led to the 
identification of a de novo heterozygous missense variant in the CREBBP gene only in the 
proband (c.5170G>A:p.E1724K). The CREBBP gene is implicated in Rubinsten-Taybi syndrome 
(RTS, MIM#180849), an autosomal dominant disease. It codes for a transcription regulatory 
factor with an intrinsic histone acetiltrasferase activity. The identified variant has been 
previously described by Sharma et al., 2010, as potentially involved in the RTS: functional 
studies conducted on the fibroblasts of this patient, harboring both this variant close to another 
one in the zinc-finger CH3 domain, display a drastic reduction in histone acetyltransferase 
activity (HAT). Defects in CBP HAT activity appear to cause problems in long-term memory 
formation. CREBBP is implied in embryonic development, growth control and homeostasis by 
coupling chromatin remodeling to transcription factor recognition. This protein acetylates both 
histone and non-histone proteins.  
In families in which the results have been validated both molecularly and clinically is ongoing 
the preparation of some manuscripts. For the other families the analysis will continue. 
 
3.3 Progeroid-like Syndrome family result 
 
 
Figure 5. Progeroid-like pedigree family. All samples were analyzed by WES.  
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3.3.1 Family 13 
The proband presented an atypical progeria clinical phenotype. Previous mutational analysis 
failed to identify variants in genes implicated in Progeria syndromes such as: Werner, Cockayne 
and Hutchinson–Gilford. Homozigosity mapping analyses gave no results. Based on these 
findings, we decided to sequence the entire family by WES. At first, an autosomal recessive 
model of transmission was hypothesized because parents were second-degree cousins (Figure 
5). Unfortunately, with this approach we did not found any plausible variant. The analysis of de 
novo variants found a non-frameshift variant (c.1812-1814delCTC:p.Ser605del) in the POLD1 




Figure 6. Sanger Sequencing of POLD1 c.1812-1814delCTC mutation. Black 
arrow indicated the starting point of the identified variant in the affected 
daughter. 
 
The same variant was reported in 4 patients with MDPL (mandibular hypoplasia, deafness, 
progeroid feature and lipodystrophy), a syndrome with progeroid features (Weedeon et al., 
2013). A critical re-evaluation of the clinical phenotype of the proband has confirmed the 
classification in MDPL syndrome. This gene encodes the catalytic subunit of the polymerase 
delta_1, which owns a polymerase activity and a 3'-5' exonuclease activity that confers the 
proof-reading skills. The delta DNA polymerase cooperates with the WRN protein, a DNA 
helicase that has a role in genomic stability. The loss of its function leads to Werner syndrome, 
which shared common phenotypic traits with the MDPL syndrome. Results of this study led to 
the publication of the paper entitled 'Mandibular hypoplasia, deafness, progeroid features and 
lipodystrophy (MDPL) syndrome in the context of inherited lipodystrophies' (Reiner et al., 
2015). 
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3.4 Epileptic Encephalopathy (EE) families results 
 
 
Figure 7. EE pedigree families. Symbols and colors are defined as follows: pac-man shape and square in red 
indicates samples analyzed by WES.  
 
3.4.1 Family 23 
The Sardinian family is composed by both parents and 2 children with a severe form of epileptic 
encephalopathy. We sequenced by WES the mother and the 2 sibs (Figure 7). Patients showed 
dystonic quadriplegia, severe intellectual disability and drug-resistant epilepsy. WES analysis 
identified two gene variants in NALCN in both probands: one stop gain maternally derived 
(c.3823C>T:p.R1275), already reported in heterozygosity in 1 individual in EXAC and a 
frameshift variant of paternal origin (c.C2496insTCATA:p.Y832fs), never described in public 
databases. These variants lie in the domain IV between segments S2 and S3 and between 
domain II (segment S6) and domain III (segment S1). Homozygous variants in these domains 
have been described associated with: i) hypotonia with psychomotor retardation and 
characteristic facies (IHPRF) (Lu B. et al., 2007); ii) infantile neuroaxonal dystrophyl with facial 
features (Köroglu et al., 2013), iii) patients affected by epilepsy (Al-Sayed et al., 2013; Gal et al., 
2016). Sanger validated both variants and clinicians fully confirmed the compatibility with the 
clinical phenotype previously reported in the literature. 
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Figure 8. Sanger sequencing of the NALCN gene. Arrows and squares indicate the two mutations present in in the 
family 23. 
 
3.4.2 Family 25 
This Brazilian family is composed of both parents and 2 daughters with EE (Figure 7), with very 
different clinical phenotype: the first daughter shows a more severe phenotype than the other 
one. The diagnosis of the first patient was based on: age at onset 1 year, febrile seizure, 
recurrence generalized crisis every day up to the age of 2 years and 4 months, epilepsy 
controlled with drugs. The other patient showed myoclonic-astatic crisis at 9 months that 
caused her cognitive impairment, hyperactivity, and attention deficit. The analysis of WES data 
allowed the identification of a heterozygous missense variant in both probands in the SCN9A 
gene (c.1964A>G:p.K655R). Singh et al., 2009 described the same variant implicated in Dravet 
syndrome (MIM#607208) and febrile seizures. In the proband with the most severe phenotype 
we have identified another de novo heterozygous variant: a stop gain in the ANKRD11 gene 
(c.5145C>G:p.Y1715*), that was found implicated in KBG syndrome (MIM#148050) and neural 
plasticity (Low et al, 2016; Goldenberg et al., 2016; Brancati et al., 2006). A critical re-evaluation 
of the clinical phenotype is in progress.  
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3.5 Osteopetrosis families result 
 
 
Figure 9. Osteopetrosis pedigree families. Samples analyzed by WES are enclosed in red squares. Symbol: 
rhombus shape, sex unknown. 
 
3.5.1 Family A 
This family is composed by consanguineous parents (third degree cousins) and 2 affected sons 
(Figure 9). In this family, no clearly pathogenic mutation was identified with exome sequencing 
analysis. While evaluating the possible impact of a 3'UTR variant on the TCIRG1 expression, we 
found a novel single nucleotide change (g.10466G>A, c.1884+146G>A) in the middle of intron 
15 of the TCIRG1 gene. This variant was present in homozygosity in the sibs and in 
heterozygosity in the parents. Further analysis indicated that this mutation did not completely 
abrogate the production of the normal transcript but reduced splicing efficiency. On this 
finding, we sequenced the same region in 33 unresolved ARO patients from our cohort and 
found 3 additional novel single nucleotide changes in a similar location and with a predicted 
disruptive effect on splicing. We further confirmed for one of them an altered splicing, 
highlighting the importance of the analysis of non-coding regions of known disease-causing 
genes (Palagano et al., 2015). 
3.5.2 Family C 
This family consists of consanguineous parents and an affected child (Figure 9). Given the 
presence of inbreeding we filtered variants assuming an autosomal recessive inheritance 
model. The analysis of candidate genes did not show significant variants. The exome analysis 
has initially led to the exclusion of the synonymous variants because known as silent and 
therefore not prone to cause diseases, but then the analysis continued including also them. 
Such analysis identified a homozygous synonymous variant in exon 12 of the TCIRG1 gene 
(c.1371 C>A:p.Thr457=) in a highly conserved position. This variant was not present in the 
public database but prediction software reported it as pathogenic. Additional molecular 
analysis showed that this variant creates a splice site (an internal acceptor site) that caused the 
loss of 67 nucleotides with the prediction of a premature termination of the protein. In this 
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case a synonymous variant erroneously flagged as silent was proved to be responsible for the 
disease (Palagano et al., 2017). 
 
3.6 Genetic hearing loss family result 
 
 
Figure 10. GHL pedigree family. Samples analyzed by WES are enclosed in red squares.  
 
3.6.1 Family 14 
The family under study is suffering from a genetic disease that causes hearing loss (GHL). The 
WES analysis of the 3 children of this consanguineous Omani family identified a homozygous 
frameshift duplication of 7pb in MYO15A gene (c.1171_1177dupGCCATCT:p.Y393Cfs*41; 
Figures 10 and 11). This gene is already known to be associated with an autosomal recessive 
form of deafness (MIM#600316). Further studies in 26 additional Omani families with GHL have 
shown that this variant was particularly widespread in the country. The development of a 
molecular allele specific assay allowed to extend the analysis to 284 subjects and to identify the 
frequency of the carriers (0.7%) and the allele frequency (0.3%) in the population. Population 
genetic studies based on haplotypes linked to this variant proved that this duplication might be 
dated to about 200-300 years ago. The high rate of consanguinity and the population 
demographic explosion have contributed to its current frequency. This population represents 
an important resource for the study of rare Mendelian diseases: inbreeding is a very important 
factor that can facilitate the discovery of disease genes with autosomal recessive inheritance 
(Palombo et al., 2017). 
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Figure 11. Segregation of MYO15A duplication in family 14. Location of the duplication in MYO15A sequence and 
of the surrounding ROH on chromosome 17. From the top: parents (first degree consanguineous) are heterozygous 
for the MYO15A c.1171_1177dupGCCATCT duplication while the three siblings displayed the duplication in a 
homozygous state; the H3M2 plot showing ROHs in chromosome 17 of one sibling of the family. ROH, Runs Of 
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Abbreviations are as follows: CS/CISS1, Crisponi/Cold Induce Sweating syndrome type 1 syndrome; SID, Syndromic 
Intellectual Disability; PLS, Progeria-like syndrome; EE, Epileptic Encephalopathy; ARO, Autosomal Recessive 
Osteopetrosis; GHL, Genetic Hearing Loss; AR, Autosomal Recessive; AD, Autosomal Dominant. 
 
  









CS/CISS1 A No NALCN  c.1800C>A p.D600E missense              
AD                       
(de novo)
Pathogenic
CS/CISS1 B No MAGEL2 c.2064-2074delTGGCAGGCACC p.689fs deletion                
AD                        
(de novo)
Pathogenic
CS/CISS1 C Yes KLHL7 c.1261T>A p.C421S missense AR Pathogenic
CS/CISS1 D No NALCN  c.1571G>A p.S524N missense            
AD                        
(de novo)
Pathogenic
CS/CISS1 E No SCN2A c.2567G>A p.R856Q missense




CS/CISS1 F Yes KLHL7 c.1022delT p.L341fs deletion AR Pathogenic
CS/CISS1 G Yes KLHL7 c.1258C>T p.R420C missense AR Pathogenic
CS/CISS1 AB No MAGEL2 c.1996insC p.Q666fs missense
AD                  
(paternal)
Pathogenic
SID 2 No CKAP2L c.571insA p.I191fs insertion AR Pathogenic
SID 3 No NCOR1 Chr 17p11.2 del CNV                       




SID 4 No CHD7 c.3082A>G p.I1028V missense             
AD                              
(de novo)
Pathogenic
SID 15 No CHD8 c.342A>C p.R114S missense




SID 21 No CREBBP c.5170G>A p.E1724K missense              
AD                            
(de novo)
Pathogenic
PLS 13 Yes POLD1 c.1812-1814delCTC p.Ser605del deletion               
AD                             
(de novo)
Pathogenic
EE 23 No NALCN c.[C2496insTCATA] ; [3823C>T] p.[Y832fs] ; [R1276] insertion; missense AR Pathogenic
EE 25 No SCN9A c.1964A>G p.K655R missense
AD                                
(paternal)
Pathogenic
EE 25 No ANKRD11 c.5145C>G p.Y1715* stopgain               
AD                               
(de novo)
Pathogenic
ARO C Yes TCIRG1 c.1371 C>A p: (Thr457=) synonimous AR Pathogenic
GHL 14 Yes MYO15A c.1171_1177dupGCCATCT p:Y393Cfs*41 duplication AR Pathogenic
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4. Discussion 
The present study contributed to further dissecting the genetic basis of different rare disorders 
in a cohort of 25 families, by using the WES approach.  
Lessons learned from WES results 
The most important result of this thesis is the finding of a new gene implicated in the 
pathogenesis of CS/CISS1 syndrome. This has been possible thanks to the availability of more 
than one patient with a very clear and homogeneous phenotype, carefully selected from an 
internal cohort of cases with clinical suspect of CS/CISS1 but negative to mutations in the 
known causative CRLF1 gene. The analysis of exome data allowed us to identify a common gene 
KLHL7, (kelch-like family member 7), in three out of the 10 families studied, harboring the 
following private and potential deleterious mutations, all in homozygous state: 
c.1261T>A:p.Cys421Ser, c.1022delT:p.Leu341Trpfs∗9 and c.1258C>T:p.Arg420Cys. To assay the 
contribution of KLHL7 to the CS/CISS1-like phenotype, we analyzed by Sanger sequencing all the 
coding sequence and intron-exon junctions of KLHL7 in the 20 remaining samples of the entire 
cohort of case subjects negative to mutations in CRLF1. We identified one additional KLHL7 
homozygous missense variant, c.1115G>A:p.Arg372Gln in another family. Three different 
mutations in KLHL7 have been previously reported to cause an autosomal dominant form of 
retinitis pigmentosa (adRP), preferentially affecting the rod photoreceptors. All of them are 
clustered in the BACK domain, which is required, along with the BTB domain, for CUL3 binding. 
In contrast, the four variants here found associated with CS/CISS1 are located close to or within 
the Kelch domain, which, from our data should not be required for CUL3 binding. Retinitis 
pigmentosa was also present in two surviving CS/CISS1 patients carrying bi-allelic KLHL7 
mutations. KLHL7 mutations are thus associated with a more severe phenotype in recessive 
than in dominant cases. Although these data further support the pathogenic role of KLHL7 
mutations in a CS/CISS1-like phenotype, they do not explain all their clinical manifestations and 
highlight the high phenotypic heterogeneity associated with mutations in this gene. 
Recognition of this “phenotypic expansion” greatly improves our understanding of the 
phenotypic consequences of variation in a known disease gene.  
Despite this excellent result, not all families with CS/CISS1 showed mutations in the CRLF1 or 
KLHL7 genes, further confirming the presence of locus heterogeneity in this rare syndrome. In 
the other families under study, we have found additional candidate genes (MAGEL2, SCN2A and 
NALCN as better explained in the result section) already known to be implicated in other 
disorders with overlapping clinical phenotype and this highlights one of the lessons that we are 
learning from WES application in the diagnosis of rare disorders. In spite of what typically 
assumed, based on the simplest concept: “one gene, one phenotype”, we are now increasingly 
discovering more complicated models, as in this case “one phenotype/many genes”. Locus 
heterogeneity has been known for some time but the frequency of overlap in phenotypic 
consequences of pathogenic variants in multiple genes is emphasized by the ongoing gene 
discovery studies.  
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The study of consanguineous families gives us an advantage in reason of the increased risk for 
autosomal recessive disorders. The families in study with probands affected by genetic hearing 
loss (GHL) come from the Sultanate of Oman, a country characterized by one of the highest 
rates of consanguineous marriages worldwide. In particular, these families have a higher 
consanguinity rate than the general Omani population, indicating a major role for recessive 
forms in the GHL. In fact, one of the main result was not only the finding of a novel homozygous 
frameshift duplication in the MYO15A gene, but more important that this duplication was 
found in a total of 8/26 (28%) families, within a 849 kb founder haplotype. These results 
emphasize important implications for the study: the possibility to design a prevention strategy 
of GHL in Oman. As discussed in many studies, the presence of founder mutations in 
populations with a genetic structure similar to the Omani population (or in our specific case 
Sardinia) offers a good opportunity for planning a population screening for common autosomal 
recessive disorders.  
Analysis pipelines should always be done considering different modes of inheritance. 
Consanguineous mates are not immune to de novo event that can cause the disorder, and 
furthermore it is likely that multiple variants may co-segregate with the disorder, so that the 
clinical phenotype can represent a result from composite phenotype. For example, in the study 
of the Progeria-like syndrome family we supposed an autosomal recessive heritability based on 
consanguinity (parents were second degree cousins) as the most probable type of transmission, 
but since we were not able to find any putative causative variant under this model, we checked 
for a possible de novo event. This led us to identify in the proband in the POLD1 gene the de 
novo c.1812-1814delCTC:p.S605del mutation. Weedon et al., 2013 described in Nature 
Genetics, the same mutation as a mutational hotspot in 4 unrelated patients, responsible for 
the MDPL syndrome, a novel variety of progeroid syndrome with lipodystrophy. A critical 
revaluation of the clinical phenotype of the proband allowed us to assess her within the MDPL 
phenotype. Additionally, we further provided indication to consider the probability that a very 
rare disease may be the result of a de novo mutation even in the presence of consanguinity. 
We had another extremely rare phenotype in our cohort: Filippi syndrome (prevalence < 
1/1,000,000 from Orphanet data). We were able to identify the causal variant in the CKAP2L 
gene and in order to validate it, we screened 6 additional patients affected by a similar 
phenotype. None of them revealed any possible causative variants in CKAP2L. The same family 
was also included in a similar study of another research group that had available a cohort of 8 
patients with Filippi syndrome. The identification of 4 different variants in such cohort 
permitted to assess that actually the CKAP2L gene was implicated in Filippi syndrome (Hussain 
et al., 2014). In extremely rare diseases it is mandatory to collect more samples with the clinical 
phenotype as homogenous as possible to test the possibility that mutations in the same gene 
are causative of the same disorder. 
Another lesson that we are constantly learning from WES studies, is that one proband can have 
a complex/blended phenotype that could be very difficult to recognize as a known/clear 
phenotype. In most cases, this is due to the presence in the same individual of more than one 
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rare Mendelian disease. For example, Yang et al., 2014 reported that, of 504 patients with a 
molecular diagnosis, 23 (4.6%) had blended phenotypes resulting from two single-gene defects 
and Retterer et al., 2015 reported analysis of 3,040 probands, identifying 25 that had two 
genetic diagnoses and three with three distinct genetic diagnoses. 
Our study confirmed the complexity involved in the evaluation of an unrecognized phenotype, 
in particular in the Intellectual Disabilities syndromic forms. We selected 9 families with cases 
affected by syndromic ID and initially for most of them we assumed a recessive model of 
transmission. Apart one family (Filippi syndrome) unfortunately this approach did not identify 
any causal variants. A change in the analysis regarding mode of inheritance, led us to the 
identification of two de novo known causative variants in two families and another de novo 
putative causative variants in one family (but in one case, only in one of two probands). This 
highlights one of the most critical factors in the disease gene identification process, which is the 
complexity of the phenotype under study even within the same family, eventually due to 
presence of more than one gene implicated and the necessity to get a detailed and 
comprehensive phenotyping of the individuals being sequenced. Then, a retrospective 
revaluation of the clinical phenotype of the patients, based on what found at a molecular level 
by WES, allowed us to reconsider particular features of the phenotype that were not 
highlighted in a preliminary evaluation, and to assess atypical syndromic forms.  
Whereas in clinical practice a genetic diagnosis often is completed once a single gene defect has 
been identified, WES studies illustrate the importance of pursuing genetic analysis until each 
individual symptom can be explained.  
For example in one family with two probands affected by different forms of epilepsy (pure and 
syndromic), we found that both have a missense heterozygous variant in the SCN9A gene 
(c.1964A>G:p.K655R), implicated in Dravet syndrome and febrile seizures, but the one with the 
most complex phenotype had also another variant heterozygous de novo, a stop gain in the 
ANKRD11 gene (c.5145C>G:p.Y1715*), implicated in KBG syndrome and neural plasticity (Low 
et al., 2016; Goldenberg et al., 2016; Brancati et al., 2006). A critical revaluation of the clinical 
phenotype by the referring clinicians, allowed us to assess the role of this variant in the clinical 
phenotype. 
WES technical issues. 
Recently several articles comprehensively evaluated the comparison of the performance of the 
4 major current exome enrichment platforms. We need to look particularly at parameters: 
target enrichment efficiency, GC bias, sensitivity in SNVs and short indel detection and coverage 
of medically interesting variants. Nowadays, all platforms showed a high performance in target 
enrichment efficiency and covered large percentage of the coding regions. Most of the coding 
regions and the medically interesting variants had at least enough coverage when using 
standard 75M reads of sequence. If we compare high‐coverage WES and WGS we can see that 
they are both able to generate sufficient coverage for reliable variant calling of 95% of the 
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regions of interest. Sequencing biases are more prominent in WES data but the cost of WGS 
makes WES a convenient prescreening technology.  
Some of the negative results in this study could be imputed to the lack of coverage of certain 
genomic regions due to exome capture probes design. For example, we sequenced 1 family 
with Osteopetrosis where we did not identify any causative variant/gene by WES. This because 
the causal variant lied in the intronic region of one of the candidate genes not covered by 
exome captures. Fortunately, in this case we analyzed a very well defined phenotype and we 
could suppose that a mutation would lie in a candidate gene for Osteopetrosis. Clearly when we 
are analyzing complex disorders like ID, we have limited information to overcome this problem. 
Importance of appropriate database. 
Common filters on WES data are based on allelic family segregation, impact on transcript 
sequence and allele frequency in a reference population to remove common polymorphisms. 
For rare diseases, it is conventionally used a filter to exclude alleles with frequency >0.01. This 
dramatically reduces the number of variants to be analyzed. However, since local population 
frequencies are not always available, several public databases are used (ESP6500, ExAC, 1000 
Genomes). In Italy, despite the large number of exome data produced by different research 
groups, clinical and genomic data are generally collected and analyzed independently of each 
other. Data-privacy requirements, non-standardized analytical methods and incompatible file 
formats are the main obstacles for data sharing. Large initiatives such as the Global Alliance for 
Genomics and Health (GA4GH) are now contributing to the definition of standards for sharing 
genomic and clinical data. To address the population frequencies issue, we created an internal 
exome database in which we aggregated WES data from ~500 samples of different ethnicity. 
The use of this additional database to filter allele frequencies, as well as platform/laboratory 
artifacts, increased the filtering power of 75%. Additionally, Sardinian families WES data were 
also filtered against a database composed by 3,500 Sardinian samples comprising ∼17.6 million 
genetic variants from WGS. About 76,000 variants that are common in our sample (frequency 
>5%) are rare elsewhere (<0.5% in the 1000 Genomes Project). Population frequencies and the 
presence of private variants e/o alleles clearly can influence the analysis of WES data of a 
peculiar population that is ancient, isolated and under many founder effects like Sardinia.  
The described filtering approaches really improved the results of our studies compared to 
standard practices. These strategies result in substantially higher quality data and define the 
optimal analytical filters for decreasing the number of variants in WES data. 
Discovery rate in our study 
A recent report on the diagnostic yield of WES in 3,040 cases at a single clinical laboratory 
(Retterer et al., 2015) has defined the 28.8% overall diagnostic yield of WES on genetically 
heterogeneous disorders. This is in line with other similar reports. The rate of discovery was 
extremely various, based on the clinical phenotype. The highest yield was for patients who had 
disorders involving hearing (55%), vision (47%), the skeletal muscle system (40%), the skeletal 
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system (39%), multiple congenital anomalies (36%), skin (32%) and the central nervous system 
(31%). Our cohort phenotype composition is high heterogeneous and overall the discovery rate 
was higher. We identified pathogenic variants in the 60% (15/25) of the families, but we have 
to consider that in some families we identified variants only in 1 of the 2 sibs analyzed. In 
addition, we identified a putative candidate variant in 12% of the families that will need to 
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5. Conclusion 
WES is a comprehensive approach to establish an early and complete characterization of 
blended or composite multigenic disease, thereby enabling precise and personalized care for 
young children with unique combined disease manifestations. WES will become the first rapid 
genetic test for children with heterogeneous or multigenic disease, which would otherwise 
require time-consuming and expensive clinical investigations. This especially applies to patients 
from consanguineous marriages where parents potentially share carriership of more genetic 
diseases than outbred marriages and identity by descent segments occur at greater rates than 
in children from outbred parents. Whereas in clinical practice a genetic diagnosis often is 
completed once a single gene defect has been identified, WES studies illustrate the importance 
of pursuing genetic analysis until each individual symptom can be explained.  
A considerable fraction of patients (about 50%) may remain unresolved after WES, due to 
incomplete exome coverage and genetic mutations that escape the technology itself (i.e. non-
coding variants, trinucleotide repeats, chromosomal rearrangements). However, in a 
proportion of these cases, although the disease-causing variant is within the WES data, for 
some reason there is insufficient evidence to support a definitive diagnosis (not enough 
information on the variant, variant acting on gene function through novel molecular 
mechanism, incorrect mode of inheritance investigated, clinical phenotype not detailed, etc...). 
To solve this gap of sensitivity, several strategies can be combined to improve and implement 
the analysis of the WES data. 
1. Detailed phenotyping; comprehensive phenotyping of patients and relatives is a key 
step in the identification of the disease gene. The identification of unrecognized 
phenotypic and locus heterogeneity is critical as well as increasing suspicion for 
phenotypic expansion and blended phenotypes.  
2. Reanalysis of WES data with methods that allow identification of CNVs; several software 
and approaches for CNV analysis have been developed. In particular, in our study we 
used the CoNIFER pipeline, with the lowest false positive rate compare to others, which 
allowed us to identify a de novo deletion in Chromosome 17p11.2 harboring the NCOR1 
gene in the two probands of family 3. This led us to hypothesize a germinal mosaicism. It 
is intriguing to note that the product of this gene is a functional partner of the MECP2 
gene which plays a role in normal brain function and is primarily associated with a loss 
of function in Rett syndrome, a neurodevelopmental disorder. 
3. Investigation of unusual modes of inheritance; analysis pipelines often consider only 
standard modes of inheritance. Autosomal dominant with incomplete penetrance, 
maternal and paternal imprinting, sex-limited phenotypes, Y-linked inheritance, or X-
linked genes in the pseudoautosomal regions or in genes that escape X inactivation are 
not usually considered. 
4. Somatic mosaicism investigation; sequencing of affected and unaffected tissue from the 
same individual revealed both cancer and non-cancer phenotypes resulting from 
somatic mosaicism. This approach needs deeper than usual sequencing, together the 
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identification of variants that are found at a lower frequency than that expected for 
heterozygous germline variants.  
Incorporating these models in the analysis pipeline can lead to successful identification of the 
causative variants and genes. WGS has been used to solve rare cases of Mendelian phenotypes. 
For example, Belkadi et al., 2015 estimated that ~3% of coding variants missed by WES were 
detected by deep coverage WGS (mean coverage 39x). Thus, WGS in addition to the obvious 
higher sensitivity for causative variants in regulatory non-coding regions may also slightly 
increase sensitivity for coding variants. However, WGS is still ~3 times more expensive and, 
importantly, much more difficult to analyze than WES because of the intrinsic difficulty in 
interpreting the functional consequences of variants in noncoding sequence. 
The development of novel genomic and functional laboratory methods, the improvement of 
known approaches, a better phenotyping of cases along with advances in the sharing of clinical 
and genetic data between groups including a better knowledge of the allelic frequencies in the 
various control populations will all be fundamental to improve the diagnostic power of the 
genetic analysis. In turn, this will allow a better understanding of the disease mechanisms and 
may allow the development of new treatments. 
Based on the results of the recent years, we could say that clinical geneticists in the future will 
have a new important role, within multidisciplinary teams, which aims to compare and combine 
the results of genetic testing in relation to the patient's phenotype. The route will start from 
the referring physician (clinical geneticist or organ specialist) and he will return, after a long and 
complex genomic and bio-computing process, for interpretation, validation and subsequent use 
of the results obtained. 
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